查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1891797

全球子宫肌瘤治疗市场：依产品类型、介绍、应用、技术/作用机制、最终用户和地区分析—市场规模、行业趋势、机会分析和预测（2026-2035 年）

Global Uterine Fibroid Drugs Market: Analysis By Product Type, Deployment, Application, Technology/Mode of Action, End-User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

子宫肌瘤治疗市场目前正经历强劲成长，预计到 2025 年将达到约 38 亿美元。预测显示，这一显着成长趋势将在未来十年持续，到 2035 年将达到惊人的 128 亿美元。 2026 年至 2035 年的复合年增长率 (CAGR) 为 14.4%，证实了全球对有效子宫肌瘤治疗方法日益增长的需求和重要性。

推动市场快速成长的关键因素很多。其中一个主要驱动因素是子宫肌瘤盛行率的不断上升，这与饮食、肥胖和环境因素等多种生活方式因素有关。随着人们对子宫肌瘤的认识不断提高，诊断技术的进步也使得越来越多的女性被诊断出患有此病，从而扩大了寻求治疗的潜在患者群体。除了盛行率的上升，患者的治疗选择也发生了显着变化，转向非手术、保留生育功能的疗法。

市场趋势

子宫肌瘤治疗市场的主要参与者包括艾伯维 (AbbVie)、辉瑞 (Pfizer)、Myovant Sciences、Hologic、波士顿科学 (Boston Scientific)、美敦力 (Medtronic) 和 Insightec 等大型製药和医疗器械公司。这些公司策略性地专注于多方面治疗方案，将荷尔蒙疗法和促性腺激素释放激素 (GnRH) 拮抗剂与先进的医疗器材相结合，以提供全面的治疗解决方案。这种方法旨在透过提供药物和手术治疗方案来满足患者的多样化需求。

在众多知名公司中，住友製药展现了强劲的财务业绩和韧性。根据2025年10月发布的修订预测，住友製药预计2025财年销售额将达到4,290亿日圆。该公司还预计截至2025年3月的财年营业利润将达到288亿日元，显示其正处于復苏和财务稳定的阶段。

2025年10月，Apotex宣布获得治疗子宫肌瘤的药物Linzagolix在加拿大的独家销售权，这是一项重大进展。此举显示Apotex对女性健康的坚定承诺，并扩大了在加拿大子宫肌瘤治疗市场的占有率。 Linzagolix已在欧盟和日本获得批准，证实了其治疗潜力和监管认可。

同时，艾伯维的药品组合也持续稳定发展。公司预计到 2027 年，其两大免疫学产品线的合併销售额将超过 270 亿美元。这一强劲的收入来源间接支持了艾伯维的研发预算，使其能够持续投资于女性健康领域，包括子宫肌瘤治疗。艾伯维雄厚的财务实力和多元化的产品线使其能够继续保持其在子宫肌瘤治疗市场的领先地位。

核心成长驱动因子

子宫肌瘤在全球的发生率极高，是最常见的妇科疾病之一。这种广泛的发病率对子宫肌瘤治疗市场产生了重大影响，并推动了对有效治疗方案的需求。根据流行病学数据（与美国疾病管制与预防中心 (CDC) 的估计一致），光是在美国，就有约 2,600 万名 15 至 50 岁的女性患有子宫肌瘤。这惊人的数字凸显了该疾病对相对年轻的育龄人群带来的沉重医疗负担。

新兴机会

引进替代疗法以减轻骨密度流失，代表子宫肌瘤治疗市场的重要机会和成长趋势。许多用于治疗子宫肌瘤的荷尔蒙疗法，特别是促性腺激素释放激素 (GnRH) 拮抗剂和激动剂，会因抑制雌激素而导致骨密度流失。这种骨密度流失会对患者造成严重风险，可能导致骨质疏鬆和骨折，并限制了这些有效疗法的长期应用。将低剂量雌激素和黄体素与主要治疗相结合的替代疗法的开发和引入，旨在抵消这种副作用，同时又不影响子宫肌瘤的治疗效果。

优化障碍

高昂的每月零售价格对患者就医构成重大障碍，并可能严重阻碍子宫肌瘤治疗市场的成长。儘管创新疗法和先进药物提供了有前景的治疗选择，但其高昂的费用往往使许多患者难以负担，尤其是那些没有全面保险或经济资源不足的患者。这种经济负担能力的挑战限制了更广泛患者群体获得这些疗法的机会，最终阻碍了市场扩张和普及。这些药物的高昂费用迫使患者做出艰难的抉择，有时甚至因为经济原因不得不延后或停止治疗。

目录

第一章：摘要整理：全球子宫肌瘤治疗市场

第二章：研究方法与架构

  • 研究目标
  • 产品概述
  • 市场区隔
  • 质性研究
    • 一手和二手资料来源
  • 量化研究
    • 一手和二手资料来源
  • 依地区划分的原始调查受访者
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第三章 全球子宫肌瘤治疗药品市场概况

  • 产业价值链分析
    • 原料供应商
    • 製造商
    • 经销商
    • 终端用户
  • 行业展望
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场成长与展望
    • 市场收入预测（2020-2035）
    • 价格趋势分析
  • 市场吸引力分析
    • 依细分市场/地理划分
    • 可操作的洞见（分析师）建议）

第四章 竞争格局概览

  • 市场集中度
  • 公司市占率分析（价值，2025 年）
  • 竞争格局分析与基准分析

第五章：全球子宫肌瘤治疗市场分析

  • 市场动态与趋势
    • 成长驱动因素
    • 限制因素
    • 机遇
    • 主要趋势
  • 市场规模及预测（2020-2035 年）
    • 依实作类型
    • 依产品类型
    • 依技术/作用机制
    • 依应用
    • 依最终用户
    • 依区域

第六章：北美子宫肌瘤治疗市场分析

第七章：欧洲子宫肌瘤治疗市场分析

第八章：亚太地区子宫肌瘤治疗市场分析

第九章：中东及非洲子宫肌瘤治疗市场分析

第十章：南美洲子宫肌瘤治疗市场分析

第十一章：公司简介

  • 艾伯维公司 (AbbVie Inc.)
  • 大元製药株式会社 (Daewon Pharmaceutical Co., Ltd.)
  • 住友製药株式会社 (Sumitomo Pharma Co., Ltd.)
  • 辉瑞公司 (Pfizer Inc.)
  • 吉赛药株式会社 (Kissei Pharmaceutical Co.,)有限公司
  • Neurocrine Biosciences, Inc.
  • 天元生物科技股份有限公司
  • ObsEva SA
  • 其他杰出球员

第 12 章：附录

简介目录
Product Code: AA12251605

The Uterine Fibroid Drugs Market is currently undergoing robust expansion, with its valuation reaching approximately US$ 3.8 billion in 2025. Projections indicate that this significant growth trajectory will continue over the coming decade, with the market expected to reach an impressive valuation of US$ 12.8 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 14.4% during the forecast period from 2026 to 2035, underscoring the increasing importance and demand for effective uterine fibroid treatments worldwide.

Several key factors are driving this rapid market growth. One of the primary contributors is the rising prevalence of uterine fibroids, which has been linked to various lifestyle factors such as dietary habits, obesity, and environmental influences. As awareness of fibroids increases and diagnostic capabilities improve, more women are being identified with this condition, thereby expanding the potential patient pool seeking treatment. In addition to the growing prevalence, there is a marked shift in patient preferences toward non-surgical and fertility-preserving treatment options.

Noteworthy Market Developments

Key players in the uterine fibroid drugs market include major pharmaceutical and medical device companies such as AbbVie, Pfizer, Myovant Sciences, Hologic, Boston Scientific, Medtronic, and Insightec. These companies are strategically focusing on a multifaceted approach that combines hormonal therapies and Gonadotropin-Releasing Hormone (GnRH) antagonists with the integration of advanced medical devices to offer comprehensive treatment solutions. This approach aims to address the diverse needs of patients by providing both pharmacological and procedural options.

Among the notable companies, Sumitomo Pharma has demonstrated strong financial performance and resilience. Based on the revised forecast released in October 2025, Sumitomo Pharma projects its fiscal year 2025 revenue to reach JPY 429 billion. The company also anticipates an operating profit of JPY 28.8 billion for the fiscal year ending March 2025, signaling a phase of recovery and financial stability.

In a significant development during October 2025, Apotex announced the acquisition of exclusive Canadian rights to linzagolix, a drug used for the treatment of uterine fibroids. This move underscores Apotex's strengthened commitment to women's health and expands its presence in the uterine fibroid market within Canada. Linzagolix has already received approval in the European Union and Japan, affirming its therapeutic potential and regulatory acceptance.

Meanwhile, AbbVie continues to make significant strides in its broader pharmaceutical portfolio. The company expects its combined sales from its immunology product duo to exceed US$ 27 billion by 2027. This robust revenue stream indirectly supports AbbVie's research and development budget, enabling continued investment in women's health assets, including uterine fibroid therapies. AbbVie's financial strength and diversified pipeline position it well to maintain leadership in the uterine fibroid drugs market

Core Growth Drivers

The prevalence of uterine fibroids is exceptionally high on a global scale, establishing it as one of the most common gynecological conditions worldwide. This widespread occurrence significantly influences the uterine fibroid drugs market, driving demand for effective treatment options. Epidemiological data, consistent with estimates from the Centers for Disease Control and Prevention (CDC), reveal that approximately 26 million women in the United States alone, aged between 15 and 50, are affected by uterine fibroids. This staggering figure underscores the substantial healthcare burden posed by the condition within a relatively young and reproductive-age population.

Emerging Opportunity Trends

The integration of add-back therapy to mitigate bone density loss represents a significant opportunity and a growing trend within the uterine fibroid drugs market. Many of the hormonal treatments used to manage uterine fibroids, particularly Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists, can lead to decreased bone mineral density as a side effect due to the suppression of estrogen. This reduction in bone density poses a serious risk for patients, potentially leading to osteoporosis and fractures, which has historically limited the long-term use of these effective therapies. The development and incorporation of add-back therapy-where low doses of estrogen and progestin are administered alongside the primary treatment-aim to counteract this side effect without diminishing the efficacy of fibroid management.

Barriers to Optimization

High monthly retail pricing presents a considerable barrier to patient access, which could significantly hamper the growth of the uterine fibroid drugs market. While innovative therapies and advanced medications offer promising treatment options, their elevated costs often place them out of reach for many patients, particularly those without comprehensive insurance coverage or adequate financial resources. This pricing challenge limits the ability of a broad patient population to benefit from these treatments, thereby restricting market expansion and adoption rates. The high cost of these drugs can lead to difficult choices for patients, forcing some to delay or forgo treatment altogether due to affordability concerns.

Detailed Market Segmentation

By Product Type, the Gonadotropin-Releasing Hormone (GnRH) antagonists have swiftly secured a dominant 33.5% market share as of 2025. This notable surge reflects a shift in treatment preferences, as these oral antagonists offer a highly attractive alternative to traditional surgical interventions. The growing adoption of these drugs underscores the market's evolving landscape, where patients and healthcare providers alike are seeking effective, non-invasive options that can manage uterine fibroids with fewer risks and greater convenience.

By Deployment, Hospitals and specialized clinical settings dominate the uterine fibroid drugs market in terms of revenue generation, accounting for a remarkable 54.36% of the total market share. This substantial figure is largely driven by the common practice of bundling pharmacotherapy with costly surgical procedures, which elevates the overall treatment expenditure within these healthcare environments. In many cases, patients receiving drug therapies for uterine fibroids in hospitals or specialized clinics are also undergoing surgical interventions such as myomectomy or uterine artery embolization, resulting in a combined treatment approach that significantly increases revenue streams from these settings.

By Technology, Hormonal modulation technologies hold the dominant position within the uterine fibroid drugs market, securing the highest market share of 44.25%. This leading share is primarily attributed to the effectiveness of these therapies in directly targeting the estrogen and progesterone receptors that play a critical role in driving tumor proliferation. Uterine fibroids are hormone-sensitive tumors, and the growth of these benign tumors is closely linked to the presence and activity of these sex hormones. By modulating hormone levels or blocking their receptors, hormonal therapies can effectively slow down or even reverse fibroid growth.

By Application, Symptomatic treatment strategies, particularly those focusing on managing heavy menstrual bleeding (HMB), dominate the uterine fibroid drugs market, accounting for a substantial 49.46% share. This significant market presence is largely because heavy menstrual bleeding is one of the most debilitating and commonly reported symptoms experienced by women suffering from uterine fibroids. The severity and impact of HMB on patients' quality of life drive strong demand for effective therapeutic options that can alleviate this distressing condition.

Segment Breakdown

By Deployment Type

  • Hospital/Clinic-Based Prescriptions
  • Retail Pharmacy/Drug Stores
  • Online/E-pharmacy

By Product Type

  • GnRH Agonists & Antagonists
  • Leuprolide
  • Relugolix
  • Selective Progesterone Receptor Modulators
  • Ulipristal acetate
  • Vilaprisan
  • Hormonal Therapies
  • Combined oral contraceptives
  • Progestins
  • Nonsteroidal Anti-Inflammatory Drugs
  • Ibuprofen
  • Naproxen
  • Other Adjunctive Therapies
  • Iron supplements
  • Herbal/OTC remedies

By Technology/Mode of Action

  • Hormonal Modulation
  • GnRH Receptor Targeting
  • Anti-inflammatory Mechanisms
  • Progesterone Receptor Modulation

By Application

  • Symptomatic Treatment
  • Fertility & Reproductive Health
  • Pre-Surgical Management
  • Post-Surgical Therapy
  • Other Applications

By End-User

  • Hospitals & Specialty Clinics
  • Gynecology & Women's Health Centers
  • Retail Pharmacies
  • E-pharmacies/Online Platforms
  • Other End-Users

By Region

  • North America
  • The US
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America is notably influenced by the aggressive pricing strategies employed for proprietary oral GnRH antagonists, which have enabled the region to capture a commanding market share of approximately 34.50%. Unlike markets where revenue is driven primarily by patient volume, the financial dynamics in North America-particularly in the United States-are shaped more significantly by a "willingness to pay" model. This approach reflects the unique structure of the US healthcare system, where pricing power and reimbursement mechanisms play a critical role in determining market success for pharmaceutical products.
  • In this context, the high prices commanded by proprietary oral GnRH antagonists have contributed substantially to revenue generation, despite the relatively stable or moderate patient base. These drugs, often positioned as premium treatment options, benefit from strong payer support and patient access programs that reflect the prioritization of innovative therapies in the region. The ability of pharmaceutical companies to negotiate favorable pricing and reimbursement terms has shifted the economic landscape of the uterine fibroid drugs market, emphasizing value-based care and willingness to invest in advanced treatments.

Leading Market Participants

  • AbbVie Inc.
  • Daewon Pharmaceutical Co., Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Pfizer Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • TiumBio Co., Ltd.
  • ObsEva SA
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Uterine Fibroid Drugs Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Uterine Fibroid Drugs Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Material Provider
    • 3.1.2. Manufacturer
    • 3.1.3. Distributor
    • 3.1.4. End User
  • 3.2. Industry Outlook
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Segment/Region
    • 3.6.2. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Uterine Fibroid Drugs Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Deployment Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Hospital/Clinic-Based Prescriptions
        • 5.2.1.1.2. Retail Pharmacy/Drug Stores
        • 5.2.1.1.3. Online/E-pharmacy
    • 5.2.2. By Product Type
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. GnRH Agonists & Antagonists
          • 5.2.2.1.1.1. Leuprolide
          • 5.2.2.1.1.2. Relugolix
        • 5.2.2.1.2. Selective Progesterone Receptor Modulators
          • 5.2.2.1.2.1. Ulipristal acetate
          • 5.2.2.1.2.2. Vilaprisan
        • 5.2.2.1.3. Hormonal Therapies
          • 5.2.2.1.3.1. Combined oral contraceptives
          • 5.2.2.1.3.2. Progestins
        • 5.2.2.1.4. Nonsteroidal Anti-Inflammatory Drugs
          • 5.2.2.1.4.1. Ibuprofen
          • 5.2.2.1.4.2. Naproxen
        • 5.2.2.1.5. Other Adjunctive Therapies
          • 5.2.2.1.5.1. Iron supplements
          • 5.2.2.1.5.2. Herbal/OTC remedies
    • 5.2.3. By Technology/Mode of Action
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hormonal Modulation
        • 5.2.3.1.2. GnRH Receptor Targeting
        • 5.2.3.1.3. Anti-inflammatory Mechanisms
        • 5.2.3.1.4. Progesterone Receptor Modulation
    • 5.2.4. By Application
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Symptomatic Treatment
        • 5.2.4.1.2. Fertility & Reproductive Health
        • 5.2.4.1.3. Pre-Surgical Management
        • 5.2.4.1.4. Post-Surgical Therapy
        • 5.2.4.1.5. Other Applications
    • 5.2.5. By End-User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Hospitals & Specialty Clinics
        • 5.2.5.1.2. Gynecology & Women's Health Centers
        • 5.2.5.1.3. Retail Pharmacies
        • 5.2.5.1.4. E-pharmacies/Online Platforms
        • 5.2.5.1.5. Other End-Users
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
  • 5.2.6.1.2.1.1. The UK
  • 5.2.6.1.2.1.2. Germany
  • 5.2.6.1.2.1.3. France
  • 5.2.6.1.2.1.4. Italy
  • 5.2.6.1.2.1.5. Spain
  • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
  • 5.2.6.1.2.2.1. Poland
  • 5.2.6.1.2.2.2. Russia
  • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. South Korea
          • 5.2.6.1.3.5. Australia & New Zealand
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa
          • 5.2.6.1.4.1. UAE
          • 5.2.6.1.4.2. Saudi Arabia
          • 5.2.6.1.4.3. South Africa
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Uterine Fibroid Drugs Market Analysis

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Deployment Type
    • 6.2.2. By Product Type
    • 6.2.3. By Technology/Mode of Action
    • 6.2.4. By Application
    • 6.2.5. By End-User
    • 6.2.6. By Country

Chapter 7. Europe Uterine Fibroid Drugs Market Analysis

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Deployment Type
    • 7.2.2. By Product Type
    • 7.2.3. By Technology/Mode of Action
    • 7.2.4. By Application
    • 7.2.5. By End-User
    • 7.2.6. By Country

Chapter 8. Asia Pacific Uterine Fibroid Drugs Market Analysis

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Deployment Type
    • 8.2.2. By Product Type
    • 8.2.3. By Technology/Mode of Action
    • 8.2.4. By Application
    • 8.2.5. By End-User
    • 8.2.6. By Country

Chapter 9. Middle East & Africa Uterine Fibroid Drugs Market Analysis

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Deployment Type
    • 9.2.2. By Product Type
    • 9.2.3. By Technology/Mode of Action
    • 9.2.4. By Application
    • 9.2.5. By End-User
    • 9.2.6. By Country

Chapter 10. South America Uterine Fibroid Drugs Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Deployment Type
    • 10.2.2. By Product Type
    • 10.2.3. By Technology/Mode of Action
    • 10.2.4. By Application
    • 10.2.5. By End-User
    • 10.2.6. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie Inc.
  • 11.2. Daewon Pharmaceutical Co., Ltd.
  • 11.3. Sumitomo Pharma Co., Ltd.
  • 11.4. Pfizer Inc.
  • 11.5. Kissei Pharmaceutical Co., Ltd.
  • 11.6. Neurocrine Biosciences, Inc.
  • 11.7. TiumBio Co., Ltd.
  • 11.8. ObsEva SA
  • 11.9. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators